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OsteoprotegerinIntermittent PTH is themajor anabolic therapy for osteoporosis while continuous PTH causes bone loss. PTH acts
on the osteoblast (OB) lineage to regulate bone resorption and formation. PTH also induces cyclooxygenase-2
(COX-2), producing prostaglandin E2 (PGE2) that can act on both OBs and osteoclasts (OCs). Because intermittent
PTH is more anabolic in Cox-2 knockout (KO) thanwild type (WT)mice, we hypothesized COX-2might contribute
to the effects of continuous PTH by suppressing PTH-stimulated differentiation ofmesenchymal stem cells into OBs.
We compared effects of continuous PTH on bone marrow stromal cells (BMSCs) and primary OBs (POBs) from
Cox-2 KOmice, mice with deletion of PGE2 receptors (Ptger4 and Ptger2 KOmice), andWT controls. PTH increased
OB differentiation in BMSCs only in the absence of COX-2 expression or activity. In the absence of COX-2, PTH
stimulated differentiation if added during the ﬁrst week of culture. In Cox-2 KO BMSCs, PTH-stimulated differen-
tiation was prevented by adding PGE2 to cultures. Co-culture of POBs with M-CSF-expanded bone marrow
macrophages (BMMs) showed that the inhibition of PTH-stimulated OB differentiation required not only
COX-2 or PGE2 but also BMMs. Sufﬁcient PGE2 to mediate the inhibitory effect was made by either WT POBs
or WT BMMs. The inhibitory effect mediated by COX-2/PGE2 was transferred by conditioned media from
RANKL-treated BMMs and could be blocked by osteoprotegerin,which interfereswith RANKL binding to its receptor
on OC lineage cells. Deletion of Ptger4, but not Ptger2, in BMMs prevented the inhibition of PTH-stimulated OB
differentiation. As expected, PGE2 also stimulated OB differentiation, but when given in combination with PTH,
the stimulatory effects of both were abrogated. These data suggest that PGE2, acting via EP4R on BMMs committed
to theOC lineage, stimulated secretion of a factor or factors that acted to suppress PTH-stimulatedOBdifferentiation.
This suppression of OB differentiation could contribute to the bone loss seen with continuous PTH in vivo.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Parathyroid hormone (PTH) is the major regulator of calcium
homeostasis through its actions on bone and kidney. PTH is critical
for bone remodeling, exerting both anabolic and catabolic effects on
bone in vivo by activating the PTH1 receptor, a G-protein coupled
receptor, on osteoblast (OB) lineage cells [1,2]. Intermittent PTH
was the ﬁrst anabolic agent approved for osteoporosis therapy in
the USA [1,3]. For reasons still not completely understood, daily injec-
tions of PTH increase bone formation more than resorption, thereby
increasing bone mass, while continuous infusion increases bone
resorption more than formation, resulting in bone loss [4–6]. Despite
the anabolic effects of PTH in vivo and the demonstration that PTH canHealth Center, 263 Farmington
860 679 1932.
.
Inc. Open access under CC BY-NC-NDstimulate OB precursors or mesenchymal stem cells (MSCs) to differ-
entiate into OBs [2,7], it has been difﬁcult to demonstrate osteogenic
effects of PTH in vitro. A number of in vitro studies have reported that
PTH present continuously in culture inhibits OB differentiation [8–11].
These observations suggest that the bone loss associatedwith continuous
PTH is not simply the result of increased resorption but may also involve
suppressed differentiation of bone-forming cells.
PTH is also a potent inducer of cyclooxygenase-2 (COX-2) and
prostaglandin (PG) production, especially PGE2, in OB lineage cells
[12,13]. PGs are locally produced lipids that have receptors on both
OB and osteoclast (OC) lineage cells [14,15]. PGE2 is abundantly
expressed in bone and can have important roles in skeletal metabolism.
Although originally identiﬁed as a resorption agonist, PGE2 also
increases bone formation in vivo [16] and OB differentiation in vitro
[14,15]. Multiple regulators of bone metabolism induce COX-2, the
major enzyme responsible for PG production. For some of these, their
induction of COX-2 enhances or mediates their stimulation of OB differ-
entiation in vitro [14,17–19]. In addition, endogenous PGs are also
necessary for normal bone repair [20] and a critical role for COX-2 and
PGE2 in triggering Wnt/β-catenin signaling in the anabolic response to license.
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receptors, EP1, EP2, EP3 and EP4, are associated with effects of PGE2.
EP2 and EP4, which activate Gαs and stimulate cAMP formation, have
predominant roles in both PGE2-stimulated bone resorption and forma-
tion [15]. EP3 is coupled to Gαi and inhibits cAMP,while EP1 acts largely
by increasing calcium ﬂux and perhaps protein kinase C (PKC) [22].
Because PTH induces PGE2 production and because PTH and PGE2
both have major actions via similar Gαs/cAMP-activated pathways
[23,24], our initial hypothesis was that PGE2 was the local mediator of
some of the anabolic actions of PTH. However, we found intermittent
PTH in vivo to be more anabolic in Cox-2 KO mice than in WT mice,
suggesting an inhibitory interaction of PTH and PGs [25]. In the current
study,we extend our initial ﬁndings on the inhibitory interaction of PTH
and PGs in vitro [26] to show that the stimulatory effect of PTH on OB
differentiation in BMSCs occurred only when COX-2 activity was absent
in both mesenchymal and hematopoietic cells. Using co-cultures and
conditioned media (CM) from bone marrow macrophages (BMMs),
we show that the inhibition of PTH-stimulated OB differentiation was
mediated by a factor or factors secreted by hematopoietic cells commit-
ted to the OC lineage in response to COX-2 produced PGs or to added
PGE2. This study reveals a new role for COX-2 and PGE2 in regulating
PTH-stimulated responses in bone and a new example of regulation of
OB differentiation by OCs.
Materials and methods
Materials
PGE2, NS398, MRE-269 (prostaglandin IP receptor agonist), dinoprost
(PGF2α receptor agonist) and all other prostanoids used were from
Cayman Chemical Company (Ann Arbor, MI). Recombinant mouse
macrophage-colony stimulating factor (M-CSF), osteoprotegerin
(OPG)/Fc-chimera and RANKL were from R&D systems (Minneapolis,
MN). Bovine PTH (bPTH; 1–34) and all other chemicals were from
Sigma (St. Louis, MO), unless otherwise noted.
Animals
Mice with disruption of Ptgs2, which produce no functional COX-2
protein, called Cox-2 knockout (KO) mice, in a C57BL/6, 129SV back-
ground were the gift of Scott Morham [27]. Ptger2 and Ptger4 KO
mice in C57BL/6, 129 backgrounds were gifts from Richard and
Matthew Breyer [28,29]. All KO mice were backcrossed more than
16 generations into the CD-1 (outbred) background. Breeding colonies
were refreshed twice a year by regenerating maintenance colonies
from mice heterozygous for the deleted or disrupted gene mated with
WT mice from Jackson Laboratory (Bar Harbor, ME). For experiments,
Cox-2 KO mice were bred by KO × KO mating, and Ptger2 and Ptger4
KO mice were bred by heterozygous × heterozygous mating. Geno-
typing protocols were as described previously [30–32]. All animal
studies were conducted in accordance to the approved protocols by
the Animal Care and Use Committee of the University of Connecticut
Health Center.
Cell cultures
All cells were cultured in a humidiﬁed atmosphere of 5% CO2 at
37 °C. Basic medium was α-MEM (Invitrogen, Carlsbad, CA), 10%
heat inactivated fetal calf serum (HIFCS), 100 U/ml penicillin, and
50 μg/ml streptomycin. Vehicles for the various treatments were as
follows: 0.1% ethanol for PGE2, all other prostanoid receptor agonists,
and NS398; 0.1% bovine serum albumin (BSA) in 1× phosphate buffered
saline (PBS) for RANKL, M-CSF and OPG; dimethyl sulfoxide for isobutyl
methyl xanthine (IBMX); and 0.001 N hydrochloric acid-acidiﬁed 0.1%
BSA in 1× PBS for PTH.Tomake bonemarrow stromal cell (BMSC) cultures, whole marrow
ﬂushed from tibiae and femora of 6–8 week old mice, plated at 106
nucleated cells/well in 6-well tissue culture dishes and cultured in OB
differentiationmedium from the timeof plating onward. Differentiation
medium consisted of basic medium plus 50 μg/ml phosphoascorbate
(Wako Pure Chemical Industry, Osaka, Japan). To study mineralization,
8 mMof β-glycerophosphate was added on day 7.Mediawere changed
every 3–4 days. Unless speciﬁed, all agents were added from the begin-
ning of culture and with each medium change. To make primary os-
teoblast (POB) cultures, calvariae from 5 to 6 neonatal mice were
dissected free of sutures, minced, washed with 1× PBS and digested
with 0.5 mg/ml of collagenase P (Roche Diagnostics, Indianapolis, IN)
in a solution of 1 ml 0.25% trypsin/EDTA and 4 ml PBS at 37 °C. Four
digests were performed for 10 min each and a ﬁnal digest for 90 min.
Digests 2–5 were pooled and plated at 4 × 104 cells/well in 6-well
dishes and cultured in differentiation media. To make bone marrow
macrophage (BMM) cultures, we followed the protocols of R. Faccio
http://www.orthoresearch.wustl.edu/content/Laboratories/2978/
Roberta-Faccio/Faccio-Lab/Protocols.aspx. Brieﬂy, 107 nucleated
bone marrow cells/well were plated in 150 mm Petri dishes (Fisher
Scientiﬁc, Pittsburgh, PA) in basic medium plus 100 ng/ml M-CSF and
expanded twice, each for three days, before being used for co-culture
or conditioned media experiments.
Co-culture and conditioned media (CM) experiments
For co-culture of BMMs and POBs, POBs were plated at 4 × 104
with 4 × 105 BMMs (1:10 ratio) per well in 6-well tissue culture
dishes and cultured in OB differentiation medium. For co-culture of
BMMs and BMSCs, BMMs were plated at 1:3 with BMSCs and cultured
in OB differentiation medium. To obtain CM, BMMs were re-plated at
6 × 104 cells/well in 12well tissue culture dishes in basic medium plus
30 ng/ml M-CSF with/without RANKL (30 ng/ml). CM were collected,
pooled and centrifuged at 800 rpm for 5 min at 4 °C to get rid of debris
and kept frozen until use. For differentiation studies with CM, freshly
isolated POBswere plated at 4 × 104/well in 6-well dishes and cultured
in 3 parts of CM and 1 part OB differentiation media with 50 ng/ml
of OPG to block RANKL–RANK interactions that might generate
osteoclasts.
Real-time (quantitative) PCR analysis
Total RNA was extracted with Trizol (Invitrogen) following
manufacturer's instructions. 2–5 μg of total RNA was DNase treated
(Ambion, Inc., Austin, TX) and converted to cDNA by the High Capac-
ity cDNA Archive Kit (Applied Biosystems, Foster City, CA). PCR
was performed in 96-well plates. Both Assays-on-Demand Gene Expres-
sion Taqman primers (Applied Biosystems) and validated Syber Green
primers (http://pga.mgh.harvard.edu/primerbank) were used for PCR.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or β-actin served
as endogenous control. All primerswere checked for equal efﬁciency over
a range of target gene concentrations. Each sample was ampliﬁed in
duplicate. PCR reaction mixture was run in Applied Biosystems Prism
7300 Sequence Detection System instrument utilizing universal thermal
cycling parameters. Data analysis was done using relative quantiﬁcation
(RQ, ΔΔCt) or the relative standard curve method.
OB and osteoclast-like cell (OCL) staining
For alkaline phosphatase (ALP) staining, cells were ﬁxed and
stained with an alkaline phosphatase kit (Sigma) using the
manufacturer's instructions. Dishes were air dried and scanned into the
computer. To assess mineralization, cells were washed with PBS, ﬁxed
in 100% V/Vmethanol on ice for 30 min and stainedwith 40 mMalizarin
red-S pH 4.2 for 10 min at room temperature. Dishes were washed with
water, air dried and scanned into the computer. For tartrate resistant acid
33S. Choudhary et al. / Bone 56 (2013) 31–41phosphatase (TRAP) staining, cells were ﬁxed with 2.5% glutaraldehyde
in PBS for 30 min at room temperature and stained by the Leukocyte
Acid Phosphatase Kit (Sigma) following company's instructions.
Oil red O staining
BMSCswere cultured for 14 days under similar conditions used for OB
differentiation but without phosphoascorbate and β-glycerophosphate
in the culture medium. Instead, 1 μM of insulin was added to the
medium on day 7 to induce formation of fat bodies. For staining, cells
were washed twice with 1× PBS, ﬁxed with 4% paraformaldehyde for
15 min at room temperature, rinsed with water and then incubated
with oil red O working solution (3 parts to 2 parts water) for 1 h at
room temperature. Dishes were washed with water, air dried and
scanned into the computer.
Prostaglandin (PG)E2 assay
Media were removed from cultured cells and frozen until assay.
PGE2 accumulation was measured using an enzyme immunoassay
(correlate-EIA™) kit following the manufacturer's instructions (Assay
Designs, Ann Arbor, MI).
Intracellular cAMP measurement
Conﬂuent POBs were treated with 3 parts CM and 1 part of OB
differentiation medium containing 0.5 mM isobutyl methyl xanthine
(IBMX) 1 h prior to adding PTH or PGE2 for 20 min. Cells were
scraped off in 400 μl/well of ice-cold ethanol. The ethanolic cell suspen-
sion was collected in tubes and centrifuged at 1500 ×g for 10 min at
4 °C. Supernatants were collected and evaporated to dryness using a
lyophilizer. cAMP was measured using an enzyme immunoassay kit
(Cayman Chemical, Ann Arbor, MI).
Statistics
All data are presented as means ± SEM. Analysis was performed
using SigmaPlot 11.0 (Systat Software, Inc.). Experiments involving
several genotypes (or combinations of genotypes in co-cultures) andA Alp mRNA
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Fig. 1. Effects of COX-2 expression or activity on PTH-stimulated OB differentiation in bone
were plated in osteogenic media and treated with vehicle (VEH) or PTH (10 nM) begun at th
real time PCR (qPCR). (A) Time course for PTH effects on AlpmRNA expression in WT and KO
NS398 (0.1 μM), a selective inhibitor of COX-2 activity, on PTH-stimulated AlpmRNA (C),Osteoc
are means ± SEM for n = 3 wells of cells. aSigniﬁcant effect of treatment relative to vehicle, ptreatments were examined by two-way ANOVA, followed by post hoc
Bonferroni pairwise multiple comparison. If data were not normally
distributed, theywere transformed (log 10) before ANOVA. Comparison
of multiple treatments to a single control was examined by one-way
ANOVA, followed by Bonferroni pairwise multiple comparison. If these
data were not normally distributed, they were examined by one-way
ANOVA on ranks, followed by Dunn's Test for all pairwise multiple
comparisons.
Results
Endogenous PGs suppressed PTH-stimulated OB differentiation in BMSC
cultures
To study effects of endogenous PGs on PTH-stimulated OB differen-
tiation,we used BMSCs fromWT and Cox-2 KOmice. Despite the consti-
tutive expression of Cox-1, very little PGE2 ismeasurable in themedia of
Cox-2 KO BMSC cultures [14,33]. It is expected that there will be “basal”
production of PGE2 in WT BMSC cultures because fresh serum stimu-
lates Cox-2 expression [34]. Because PGE2 can stimulate OB differentia-
tion, this basal production often leads to increased OB differentiation in
vehicle-treated WT compared to KO or NSAID-treated WT cultures, as
seen here (e.g., Figs. 1A–E). PTH is expected to further induce Cox-2 ex-
pression and PGE2 production in these cultures [12,13].
BMSCswere culturedwith PTH (10 nM) added at plating of cells and
with eachmedia change. This protocol should provide continuous expo-
sure to PTH because PTH has been shown to be stable in culture up to
72 h between medium changes [35]. As we showed previously [26],
PTH stimulated OB differentiation in Cox-2 KO, but not WT, BMSC cul-
tures. PTH stimulated marked increases in Alp and Osteocalcin mRNA
(Figs. 1A,B) and alizarin red staining (data not shown) in KO cultures,
but not in WT cultures. In WT cultures, PTH decreased, or tended to
decrease, markers of OB differentiation relative to vehicle treatment.
The stimulatory effect of PTH in Cox-2 KO cultures was seen by day 7 of
culture and was maintained throughout 3 weeks of culture (Fig. 1A).
To determine if the inhibitory effect of COX-2 was due to COX-2
activity, we examined treatment with a selective inhibitor of COX-2
activity, NS398. NS398 restored the ability of PTH to stimulate Alp and
Osteocalcin mRNA expression and alizarin red staining in WT cultures,B Osteocalcin mRNA
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alcinmRNA (D) andmineralization (E) inWT BMSCs, measured at 14 days of culture. Bars
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Fig. 2. PTH regulation of adipogenesis and osteoclast-like cell (OCL) formation in BMSCs fromWT and Cox-2 KO mice. BMSCs were cultured in osteogenic media, except as noted, and
treated with vehicle (VEH) or PTH (10 nM). mRNA expression was measured by qPCR. (A) Adiponectin and (B) PparγmRNAmeasured at 14 days of culture. Data are from same exper-
iment as shown in Figs. 1 (A,B). Bars aremeans ± SEM for n = 3. aSigniﬁcant effect of treatment relative to vehicle, p b 0.01. bSigniﬁcant effect of genotype, p b 0.01. (C) Oil redO staining
in BMSCs cultured for 14 days. Cells were cultured without phosphoascorbate and β-glycerophosphate. Insulin (1 μM) was added to the medium on day 7. (D) Tartrate resistant acid
phosphatase (TRAP) staining in BMSCs at day 7 of culture. (E) Alkaline phosphatase (ALP) staining of colonies in PTH-treated Cox-2 KO BMSCs at day 9 of culture. (F) TRAP staining
(40× magniﬁcation) at day 7.
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(Figs. 1C–E).
Because there may be reciprocal effects between OB and adipocyte
differentiation [36,37] and because PTH can regulate adipocyte differ-
entiation [35], we examined expression of Adiponectin, a marker of
adipocytes, and Pparγ, a transcription factor that may be important not
only for stimulating adipogenesis but also for suppressing osteogenesis
[38]. PTH inhibited both Adiponectin and Pparγ expression on day 14 of
culture in WT, but not Cox-2 KO, cultures (Figs. 2A,B). Similar patterns
were seen on day 21 (data not shown). Oil red O staining for mature
adipocytes was consistent with the gene expression (Fig. 2C). Hence,
differentiation of bothOBs and adipocytes in these cultureswas inhibited
by endogenous PGs.A Alp mRNA
KOWT
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mentwith PTH. BMSCswere given PTH for the days indicated on x-axis. All cultureswere extrac
of PTH, p b 0.01. bSigniﬁcant effect of genotype, p b 0.01. (B) Comparison of the mineralizatio
were stained for alizarin red after 14 days of culture.BMSC cultures differ from the marrow cultures used for studying
OC differentiation in that they are plated at lower density and have
phosphoascorbate in the media. PTH stimulated formation of osteoclast-
like cells (OCLs), deﬁned as tartrate resistant acid phosphatase (TRAP)
multinucleated cells, during the ﬁrst week of culture in both WT
and Cox-2 KO BMSCs. OCLs were seen at days 4–5 of culture and
were abundant by day 7, resulting in the appearance of “empty” areas
in the center of ALP stained colonies (Figs. 2D–F). No OCLswere formed
in control cultures (Fig. 2D). OCLs had largely disappeared by days 12–14
(data not shown). It was not possible to quantify OCL number in these
cultures since most were covered by a canopy of cells. Although there
appeared grossly to be little difference in TRAP staining between WT
and KO cells, these observations raised the possibility that differences-14
NS398VEH VEH NS398
VEH
NS398 or VEH 
from d 3-7
PTH
NS398 or VEH 
from d 0-14
B Alizarin Red Staining
d Cox-2 KO mice were plated in osteogenic media and treated with vehicle (VEH) or PTH
easured by qPCR. (A) Comparison of the AlpmRNA response to different periods of treat-
ted for RNA after 14 days. Bars aremeans ± SEM for n = 3wells of cells. aSigniﬁcant effect
n response to PTH in WT BMSCs given NS398 for 3–7 days versus 0–14 days. All cultures
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be due to space-occupying OCLs.
To determine the window of time during which PTH needed to be
present to stimulate OB differentiation, we cultured BMSCs for different
periods of time with PTH and measured AlpmRNA at day 14 of culture.
When PTH was given to Cox-2 KO BMSCs from days 0–3, 3–7 or 0–7 of
culture, it increased Alp mRNA (Fig. 3A). However, when PTH was not
started until day 7 of culture, it did not increase OB differentiation.
PTH did not stimulate AlpmRNA expression in WT BMSCs when given
for any period of time. As further conﬁrmation that PTH acted during
the ﬁrst week of culture to stimulate OB differentiation, we treated
WT BMSCs with NS398 from days 3 to 7 or from days 0 to 14 and
measured mineralization on day 14. PTH stimulated mineralization
to a similar extent in both cases (Fig. 3B).
Because the window for PTH stimulation of OB differentiation in
Cox-2 KO cultures was early in culture and because PGs cause PTH
to decrease both OB and adipocyte differentiation, it is possible that
PGs are modulating the actions of PTH on MSCs, which are likely to
be available only early in culture.
Suppression of PTH-stimulated OB differentiation required both PGs and
hematopoietic cells
Because OCLs formed early in BMSC cultures, beginning during the
window of time for the stimulatory effects of PTH, we postulated that
OC lineage cells might play a role in the inhibitory effects of PGs. If so,
the inhibitory effect should not be seen in primary osteoblasts (POBs).
However, in our previous study, we also observed an inhibitory effect
of PGs on PTH-stimulated OB differentiation in POB cultures [26].D
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media and treated with vehicle (VEH), PTH (10 nM), or other agents begun at the time of p
Stimulation of TRAP-staining cell formation in POBs cultured from WT mice. Cultures were
Cox-2 KO POBs treated for 14 days. (C) Effect of NS398 (1 μM), an inhibitor of COX-2 activ
(1 μM) or their combination, PTH+PGE2, all in the presence of NS398 (1 μM), on Alp mRN
in the presence of NS398 (1 μM). Cells were treated with the same agonists as in (D) for 1
PGE2 (10 nM), or PTH + PGE2 in the presence of osteoprotegerin (OPG, 50 ng/ml), an in
21 days. Bars are means ± SEM for n = 3 wells of cells. aSigniﬁcant effect of treatmen
PTH + PGE2 relative to either treatment alone, p b 0.01. Nd = below limits of assay.When we examined our POB cultures for the ability to form OCLs,
we found that both PTH, which increases RANKL mRNA expression
in POBs, and exogenous RANKL induced formation of cells that stained
for TRAP in these cultures (Fig. 4A). If the minced calvarial pieces
were carefully washed multiple times to eliminate marrow, many
fewer TRAP staining cells were seen (Fig. 4A). With the increased
washing of calvarial pieces, we found that PTH stimulated OB differen-
tiation in WT POBs (Fig. 4B) and that NS398 had no effect on
PTH-stimulated OB differentiation (Fig. 4C).
On the assumption that PGE2 might be the PG mediating the inhibi-
tory effects of COX-2, we examined the effects of adding PGE2 to PTH
(Fig. 4D). (We continued to use either Cox-2 KO POBs or treat with
NS398 because chronic exposure to PGE2 in themediamight down reg-
ulate responses to added PGE2.) PTH or PGE2 alone stimulated Alp
mRNA in POBs at 14 days of culture, but the combination of PTH and
PGE2 had no greater effect than either agent alone, suggesting that
some inhibition remained (Fig. 4D). However, treatment of POBs with
PTH, PGE2 and the combination for 15 min had an additive effect on
cAMP production (Fig. 4E), the pathway through which both agents
are supposed to produce anabolic effects. Because we had previously
observed that the combination of PGE2 and PTH had additive or greater
effects on OCL formation in bone marrow cultures [31], we treated
cultures with OPG, which interrupts the RANK–RANKL interaction. In
the presence of OPG, the combination of PTH and PGE2 had additive
effects on PTH-stimulated OsteocalcinmRNA at 14 days (Fig. 4F).
These data suggest that RANKL-stimulated hematopoietic cells
were necessary for suppression of PTH-stimulated OB differentiation.
In addition, the data indicate that PGE2 itself was not the factor that
acted on POBs to inhibit PTH-stimulated OB differentiation.A
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osteoblast (POB) cultures. POBs from WT and Cox-2 KO mice were plated in osteogenic
lating and given with each media change. Gene expression was measured by qPCR. (A)
treated with PTH or RANKL (30 ng/ml) for 8 days. (B) Alp mRNA expression in WT and
ity, on Alp mRNA expression in WT POBs at 14 days. (D) Comparison of PTH or PGE2
A expression at 14 days. (E) Measurement of intracellular cAMP in WT POB cultures
5 min in the presence of IBMX (0.5 mM). (F) Treatment of Cox-2 KO POBs with PTH,
hibitor of RANKL-mediated osteoclast formation. Osteocalcin mRNA was measured at
t, p b 0.01; bp b 0.05. cSigniﬁcant effect of genotype, p b 0.05. dSigniﬁcant effect of
Table 1
Medium PGE2 and Osteocalcin mRNA expression in co-cultured POBs and BMMs from
WT and COX-2 KO mice treated with vehicle or PTH (10 nM).
WT BMMs KO BMMs
WT POBs KO POBs WT POBs KO POBs
(1) PGE2 (nM) accumulated in media during ﬁrst week of culture
Vehicle 6.8 ± 0.1 6.4 ± 0.2 3.8 ± 0.1a,b nd
PTH 14.2 ± 0.4c 7.2 ± 0.2a,c 11.3 ± 0.2a,b,c nd
(2) Osteocalcin mRNA at day 14 of culture
Vehicle 1.71 ± 0.13d 1.33 ± 0.07d 1.07 ± 0.12d 0.55 ± 0.05
PTH 0.12 ± 0.01c,d 0.09 ± 0.01c,d 0.19 ± 0.02c,d 10.9 ± 1.24c
(1) PGE2 data are means ± SEM for n = 3. Nd is not detectable. Media were collected
at time of media change (day 3 and day 7) and equal aliquots pooled for measurement.
(2) Osteocalcin data are means ± SEM for n = 4. For both sets, data were log 10
transformed before two-way ANOVA analysis to achieve normal distribution.
a Signiﬁcantly different from WT BMMs + WT POBs, p b 0.01.
b Signiﬁcantly different from WT BMMs + KO POBs, p b 0.01.
c Signiﬁcant effect of PTH, p b 0.01, p b 0.05.
d Signiﬁcantly different from KO BMMs + KO POBs, p b 0.01.
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prevent the PTH-stimulated OB differentiation
The addition of WT BMMs to Cox-2 KO BMSCs blocked the
PTH-stimulation of OB differentiation (Fig. 5A). When Cox-2 KO POBs
were co-cultured with BMMs fromWT or Cox-2 KO mice, the presence
ofWTBMMs, but not KOBMMs, prevented the PTH-stimulated increase
in OB mineralization (Fig. 5B). To conﬁrm a role for cells committed to
the OC lineage in mediating the inhibitory effect of PGs, we treated
BMSCs with OPG. When OPG was present, PTH stimulated OB differen-
tiation in WT as well as Cox-2 KO BMSCs (Figs. 5C–E). Although OPG is
reported to have direct effects on OB differentiation [39], we did not
see effects of OPG alone on OB differentiation.We considered the possi-
bility that OPGmight block inhibitory effects by suppressing PG produc-
tion in these cultures. Therewas a reduction, not statistically signiﬁcant,
in PTH-stimulated medium PGE2 accumulation in the presence of OPG
from 7.3 ± 0.4 to 4.4 ± 1.6 nM, which, as will be discussed below,
should not have prevented the inhibitory effects. These results are
consistent with the previous data suggesting that the cells mediating
the inhibition of PTH-stimulated OB differentiation are committed to
the OC lineage.
Although OBs are generally assumed to be the major source of PGs
in bone, these co-culture results suggested that WT BMMs produced
sufﬁcient PGs to mediate the inhibitory effects. To examine the relative
roles of OB and OC lineage cells in producing PGE2 in these cultures, we
measured medium PGE2 accumulation in co-cultures of POBs and
BMMs fromWT and Cox-2 KOmice and compared with OB differentia-
tion measured by Osteocalcin mRNA (Table 1). As expected, when KO
POBswere co-culturedwith KO BMMs,medium PGE2was undetectable
in vehicle or PTH-stimulated cultures [31,33].WT BMMs (plated at 10:1
ratio with POBs) made more PGE2 under basal conditions than WT
POBs. The basal level of PGE2 production by POBs was likely due toC BMSCs: Alp mRNA D BMSCs: Osteocalc
-OPG + OPG
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Fig. 5. Effects of bone marrow macrophages (BMMs) on PTH-stimulated OB differentiation.
macrophages (BMMs). All cultures were in osteogenic media and treated with vehicle (VEH
change. Gene expression was measured by qPCR. (A) Alizarin red staining at 14 days in Cox-2
of 1:3 to BMSCs. (B) Alizarin red staining at 14 days in Cox-2 KO POBs co-cultured with BM
(D) Osteocalcin mRNA expression in WT and Cox-2 KO BMSCs at 14 days following treat
RANKL-RANK binding. (E) Alizarin red staining at 14 days of culture in WT BMSCs treate
cells. aSigniﬁcant effect of PTH, p b 0.01. bSigniﬁcant effect of genotype, p b 0.01. cSigniﬁcanthe serum induction of COX-2 [34]. PTH stimulated PGE2 production
2- to 3-fold in co-cultures withWT POBs but had little effect in cultures
with KO POBs, consistent with the expected absence of PTH receptors
on BMMs. The small increase in PGE2 in the WT BMM, KO POB
co-culture might be due to PTH-stimulated RANKL expression in the
POBs, which subsequently induced COX-2 in BMMs [40].
In vehicle-treated cultures, the Osteocalcin levels decreased as
PGE2 levels decreased (Table 1). PTH-stimulated Osteocalcin mRNA
expression was increased 20-fold relative to vehicle treatment in KO
BMM-KO POB cultures, which had no detectable PGE2 production. In
all other combinations, which contained WT POBs or WT BMMs and
did produce measurable PGE2, PTH-stimulated Osteocalcin expressionin mRNA
a,c
a,b
VEH
+ OPG- OPG
PTH
E BMSCs:  Alizarin Red Staining
OBs: Cox-2 KO    Cox-2 KO  Cox-2 KO    
MMs:        -- WT         Cox-2 KO
Co-cultures: Alizarin Red Staining
VEH
PTH
+ OPG
WT KO
BMSCs or POBs from WT and Cox-2 KO mice were cultured alone or with bone marrow
), PTH (10 nM), or other agents began at the time of plating and given with each media
KO BMSCs co-cultured with BMMs from KO andWTmice. BMMs were plated at a ratio
Ms from WT and KO mice. POBs were plated at a ratio of 1:10 to BMMs. (C) Alp and
ment with PTH, plus/minus osteoprotegerin (OPG, 30 ng/ml), which interferes with
d with PTH plus/minus OPG (50 ng/ml). Bars are means and SEM for n = 3 wells of
t effect of OPG, p b 0.01.
37S. Choudhary et al. / Bone 56 (2013) 31–41was inhibited relative to the KO-KO combination. Hence, either POBs or
BMMs expressing COX-2 were sufﬁcient to prevent the PTH-stimulated
OB differentiation in this culture system.
Exogenous PGE2 suppressed PTH-stimulated OB differentiation in BMSCs
In many of our experiments in BMSC cultures (Figs. 1,3) or in
cultures with both POBs and BMMs (Table 1), but not in POBs cultured
alone (Fig. 5), PTHgiven in the presence of COX-2 expression resulted in
decreased Alp or Osteocalcin expression relative to vehicle-treated
cultures. Since some of the OB differentiation in vehicle-treated cultures
is explainable by the serum induction of COX-2 expression and endog-
enous PGE2 production (Table 1) [34], this observation suggests that, in
the presence of BMMs, the stimulatory effect of endogenous PGE2 onOB
differentiation was suppressed in the presence of PTH.
To look at this possibility more directly, we treated BMSC cultures
with PTH (10 nM), PGE2 (10 nM) and the combination (Fig. 6A). PGE2
stimulated Bone sialoprotein (Bsp) mRNA at 14 days in both WT and
Cox-2 KO BMSCs. (The small but signiﬁcant increase in the effects of
PGE2 in KO cells has been seen before and may be due to down regu-
lation of PGE2 receptors due to chronic exposure to endogenous PGE2
in WT cultures). Although both PTH and PGE2 individually stimulated
Bsp mRNA expression in KO cultures, the combination of PTH and
PGE2 had no stimulatory effect.A Bsp mRNA
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Fig. 6. Effects of exogenous PGs on PTH-stimulated differentiation in BMSCs. BMSCs were trea
media change. (A) Bone sialoprotein (Bsp)mRNA expression inWT and Cox-2KOBMSCs treated
aSigniﬁcant effect of treatment relative to vehicle, p b 0.01, bp b 0.05. cSigniﬁcantly different fro
of genotype, p b 0.01. (B) AlpmRNA in Cox-2 KOBMSCs at 14 days of culture: effect of adding v
all doses of PGE2 alone increased AlpmRNA relative to vehicle (p b 0.01). The combination of PT
mRNA in Cox-2KOBMSCs at 14 days of culture: effect of adding varying doses of PTH to PGE2 (1
mRNA relative to vehicle (p b 0.01). The combination of PTH and PGE2 at all doses reduced Alpm
14 days of culture: effect of OPG (50 ng/ml). Symbols are means ± SEM for n = 3wells. aSign
PGE2 alone, p b 0.01. cSigniﬁcant effect of OPG, p b 0.01. (E)OsteocalcinmRNA in Cox-2 KO BMS
for n = 3wells. aSigniﬁcant effect of treatment relative to vehicle, p b 0.01. bSigniﬁcantly differ
all other combinations of PTH and PG, p b 0.01.To better understand the dose range over which these effects
occurred, we treated Cox-2 KO BMSCs with PTH (10 nM) ± PGE2
(0.1 nM to 0.1 μM) for 14 days (Fig. 6B). PTH and all doses of PGE2
alone increased Alp mRNA relative to vehicle, but PTH combined with
PGE2, at any dose, resulted in decreased Alp mRNA expression relative
to either PTH or PGE2 alone. Similarly, the combination of a single
dose of PGE2 (10 nM) with several doses of PTH (0.1 nM to 10 nM)
decreased Alp mRNA expression relative to PGE2 or PTH alone
(Fig. 6C). To examine a role for BMMs in the inhibition of OB differenti-
ation by the combination of PTH and PGE2, we examined the effects of
OPG (Fig. 6D). In the presence of OPG, the combination of PTH and
PGE2 had additive stimulatory effects on OsteocalcinmRNA.
Other PGs could be involved in the inhibitory effect of COX-2.
To screen for some other likely candidates, we treated Cox-2 KO
BMSCs with PGE2 and compared with other PG receptor agonists, all
at 0.1 μM (Fig. 6E). Because PGI2 is unstable, we used MRE-269, a sta-
ble IP receptor agonist. For PGF2α, we used dinoprost, an FP receptor
agonist. All cultures were with Cox-2 KO cells because PGs can induce
COX-2 expression andmake PGE2,which could confound the comparison
[41]. PGE2 was the only prostanoid that stimulated Osteocalcin mRNA,
and the only prostanoid that resulted in loss of the stimulatory effect
when added to PTH.
These data on exogenous PGE2, along with the previous data on en-
dogenous PGs, can be summarized as follows (Table 2). The inhibition ofog M)
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for 14 dayswith PTH (10 nM) and PGE2 (10 nM). Bars aremeans ± SEM for n = 3wells.
mPTH alone, p b 0.01. dSigniﬁcantly different fromPGE2 alone, p b 0.01. eSigniﬁcant effect
arying doses of PGE2 to PTH (10 nM). Symbols aremeans ± SEM for n = 3wells. PTH and
Hand PGE2 at all doses reduced AlpmRNA relative to either agent alone (p b 0.01). (C) Alp
0 nM). Symbols aremeans ± SEM for n = 3wells. PGE2 and all doses of PTH increasedAlp
RNA relative to either agent alone (p b 0.01). (D)OsteocalcinmRNA in Cox-2KOBMSCs at
iﬁcant effect of treatment relative to vehicle, p b 0.01. bSigniﬁcantly different from PTH or
Cs at 14 days of culture: effect of different PGs (all at 0.1 μM). Symbols aremeans ± SEM
ent from all other PGs alone, p b 0.01. cSigniﬁcantly different from PTH or PGE2 alone and
Table 2
Summary of effects of PTH, COX-2/PGE2 and BMMs on OB differentiation.
Treatments Cells
OBs with BMMs OBs without BMMs
COX-2
in OB or BMM
No COX-2 COX-2 No COX-2
PTH − + + +
PGE2 + + + +
PTH + PGE2 − − ++ ++
38 S. Choudhary et al. / Bone 56 (2013) 31–41PTH-stimulatedOBdifferentiationwas only seen in the presence of both
BMMs and endogenous or exogenous PGs. In the absence of BMMs,
there was no inhibitory effect of COX-2 or PGE2, and PTH and PGE2
were additive. In the presence of BMMs, treatment with the
combination of PTH and PGE2, each of which was stimulatory alone,
produced no stimulatory effect.
Inhibition of PTH-stimulated OB differentiation required expression of
EP4 receptors (EP4) on BMMs
The need for BMMs to be present in order to see inhibition of PTH
effects suggests that PGs are acting on BMMs to cause the inhibition.
As indicated by the studies above, PGE2 is a likely candidate for the PG
involved. The effects of PGE2 in bone have been most often associated
with cAMP production and protein kinase A (PKA) activation,
suggesting an important role for the PGE2 receptors EP2 and EP4,
which are both coupled to Gαs. Both EP2 and EP4 are reported to bePOBs: --------------- Cox-2 KO -------------------
BMMs: --- WT Cox-2 KO Ptger4 KO
C Co-cultures: Osteocalcin mRNA
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Fig. 7. Effects of deleting Ptger2 and Ptger4 on PTH-stimulated OB differentiation. All cells we
with each media change. Gene expression was measured by qPCR. (A) Osteocalcin mRNA an
BMSCs were treated with vehicle (VEH), PTH (10 nM) and PGE2 (10 nM). (C) OsteocalcinmR
14 days. POBs were plated at a ratio of 1:10 to BMMs. (D) TRAP staining in POB and BMM
p b 0.01. bSigniﬁcant effect of genotype compared to WT, p b 0.01, cp b 0.05.expressed bybonemarrowmacrophageOCprecursors [42]. To examine
the roles of these receptors, BMSCs from WT and Ptger2 or Ptger4 KO
mice were cultured with PTH (Figs. 7A,B). PTH stimulated OB differen-
tiation in Ptger4 KO cultures but inhibited inWT and Ptger2KO cultures.
For comparison, we treated these cultures with PGE2. PGE2 stimulated
Osteocalcin expression in both WT and Ptger2 KO BMSC (Figs. 7A,B).
As expected from previous experiments, which showed a major role
for EP4 in the osteogenic effects of PGE2 [43,44], deletion of Ptger4 greatly
reduced PGE2-mediated OB differentiation.
To determine if EP4 on BMMswas necessary for the suppression of
PTH effects, we co-cultured Cox-2 KO POBs with BMMs from WT,
Cox-2 KO and Ptger4 KO mice (Fig. 7C). As expected, PTH stimulated
Osteocalcin expression in POBs cultured without BMMs and in POBs
co-cultured with Cox-2 KO BMMs but not with WT BMMs. There
was no inhibition of PTH-stimulated Osteocalcin expression in POBs
co-cultured with Ptger4 KO BMMs. To rule out the possibility that
the effect of Ptger4 deletion was due to preventing formation of OC
precursors, we compared the co-cultures for TRAP staining. There was
no increase in TRAP staining with PTH in cultures without BMMs. PTH
increased TRAP similarly in all the other co-cultures (Fig. 7D). Hence,
Ptger4 in BMMs was required for the inhibitory effects of PGs on
PTH-stimulated OB differentiation.
The inhibitory effect was transferred by conditioned media (CM) from
RANKL-stimulated BMMs
To determine if the inhibition was mediated by cell–cell contact or
by secretion of a soluble factor, POBs were co-cultured with CMB BMSCs:  Alizarin Red
   Staining
VEH PGE 2 PTH
Ptger4
KO
Ptger2
KO
WT
D Co-cultures: TRAP Staining
VEH
PTH
POBs:  ----------------- Cox-2 KO -------------------
BMMs: --- WT Cox-2 KO Ptger4 KO
re cultured in osteogenic media. Treatments were begun at the time of plating and given
d (B) alizarin red staining in WT, Ptger2 KO and Ptger4 KO BMSCs at day 14 of culture.
NA in Cox-2 KO POBs co-cultured with BMMs fromWT, Cox-2 KO and Ptger4 KOmice for
co-cultures at day 8. Bars are means ± SEM for n = 3. aSigniﬁcant effect of treatment,
39S. Choudhary et al. / Bone 56 (2013) 31–41collected from WT and Cox-2 KO BMMs. Cox-2 KO POBs were used in
all experiments, and Alp or Osteocalcin mRNA was measured after
14 days of culture. Because RANKL was added to most BMM cultures
before obtaining the CM, all POB cultures were done in the presence
of OPG to prevent OCL formation.
In the ﬁrst experiment, CM was collected from BMMs expanded
for 5 days with M-CSF and compared with CM from BMMs treated
with both M-CSF and RANKL for 0–3 days or 3–5 days (Fig. 8A). CM
from WT, but not Cox-2 KO, BMMs treated with both M-CSF and
RANKL inhibited the PTH stimulation of Osteocalcin in POBs. CM
from WT BMMs treated only with M-CSF did not signiﬁcantly inhibit.
Inhibition by CM fromWT BMMs cultured for 0–3 days was similar to
that from BMMs cultured for 3–5 days. The 3 day BMM culture, treated
with bothM-CSF and RANKL,was used in all further experiments. Some
TRAP + multinucleated cells were present in both WT and KO BMM
cultures treated for 3 days with M-CSF and RANKL (data not shown).
Although CM from WT BMMs inhibited PTH-stimulated Osteocalcin
expression, WT CM did not inhibit Osteocalcin in vehicle-treated cultures
compared to cultures without CM (Fig. 8B). In addition, CM from Cox-2
KO BMMs had no effect on vehicle-treated POBs.
To look at the effects of CM on responses to exogenous PGE2, we
examined effects of WT and Cox-2 KO CM on PGE2-and PTH + PGE2-
stimulated Osteocalcin expression (Fig. 8C). WT CM did not inhibit
PGE2 stimulated Osteocalcin expression but did inhibit the stimulation
of expression by PTH and PTH + PGE2. In the presence of Cox-2 KO CM,
the combination of PTH and PGE2 had additive effects on OsteocalcinDays: 0 - 5 0 - 3 3 - 5
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Fig. 8. Effect of conditionedmedia (CM) fromBMMcultures on PTH-stimulated POB differentia
with M-CSF (30 ng/ml) alone or with both M-CSF and RANKL (30 ng/ml). POBs ± CM were t
were done in the presence of OPG (50 ng/ml) to block osteoclast formation. Gene expression
of BMM culture, on PTH-stimulated Osteocalcin expression in POBs. BMMs were cultured with
periment, all further experiments usedCM fromBMMs cultured for 3 dayswith bothM-CSF and
Osteocalcin expression in POBs. (C) Effects ofWT and Cox-2 KO CM on the ability of exogenous
CM from WT, Ptger2 KO, and Ptger4 KO BMMs on Alp mRNA expression in POBs. Bars are m
bSigniﬁcant effect of genotype (compared to WT) of BMMs from which CM was obtained, p b
from PGE2 alone, p b 0.01.mRNA, conﬁrming that a factor (or factors) made by BMMs expressing
COX-2, not only inhibited PTH-stimulated Osteocalcin but also caused
the inhibitory interaction of PTH and PGE2.
To conﬁrm the role of EP4 in the inhibitory effect, we treated Cox-2
KO POBs with CM fromWT, Ptger2 and Ptger4 KO BMMs (Fig. 8D). PTH
inhibited Alp expression relative to vehicle in the presence of CM
from WT BMMs or Ptger2 KO BMMs. In contrast, in the presence of
CM from Ptger4 KO BMMs, PTH stimulated Alp expression. Hence, it
seems likely that PGs produced by BMMs acted on BMMs via EP4 to
produce one or more soluble factors that inhibited the osteogenic
effects of PTH on POBs. This observation supports the likelihood that
the PG involved in the inhibitory effects is PGE2.
Discussion
This study conﬁrms and expands upon our previous observation
that COX-2 produced PGs inhibit PTH-stimulated OB differentiation
in BMSCs [26]. When COX-2 expression or PG production was absent,
PTH markedly stimulated OB differentiation in BMSCs. The window for
the stimulatory effect was the ﬁrst week of culture, and this observation,
in conjunction with similar effects of PTH on both OB and adipocyte
differentiation, suggests that PTH was acting on OB precursors or MSCs,
consistent with reported effects of PTH on OB precursors or MSCs
in vivo [2,7].
Because PTH is stable in culture up to 72 h between medium
changes [35], our culture conditions provided continuous exposure of0.0
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tion. POBs in all experimentswere from Cox-2KOmice. CMwere taken fromBMMs treated
reated with vehicle (VEH), PTH (10 nM) or the combination for 14 days. All POB cultures
was measured by qPCR. (A) Comparison of effects of CM, pooled from different periods
M-CSF only for 5 days or with both M-CSF and RANKL for 0–3 or 3–5 days. After this ex-
RANKL. (B) Comparison of effects ofWTand Cox-2KOCMon vehicle- and PTH-stimulated
PGE2 (0.1 μM) and PTH + PGE2 to stimulate Osteocalcin expression in POBs. (D) Effects of
eans ± SEM for n = 3. aSigniﬁcant effect of treatment (compared to vehicle), p b 0.01.
0.01. cSigniﬁcantly different from PGE2 and PTH alone, p b 0.01. dSigniﬁcantly different
40 S. Choudhary et al. / Bone 56 (2013) 31–41cells to PTH, which in most in vitro studies has resulted in inhibition of
OB differentiation. Because intermittent PTH is anabolic in vivo but con-
tinuous PTH is catabolic, it is often assumed that PTH must be applied
intermittently in vitro in order to be osteogenic. This assumption was
strengthened by positive effects on OB differentiation when cells had
short, transient exposure to PTH [8,10,45]. However, the brief duration
of PTH exposure is usually accomplished by removing PTH-containing
media and replacing with fresh media. Since this procedure also
removes PGs that accumulate in themedia, it is possible that the osteo-
genic effects in such experiments were really due to the removal of PGs
that inhibited osteogenic effects of PTH.
The inhibitory effects of PGs on OB formation did not occur
in vehicle-treated BMSC cultures but only in PTH-treated BMSCs. In
these cultures, OCLs were formed in response to PTH during the same
“window” of time that PTH had its stimulatory effect. The inhibitory
effects of PGs did not occur in POBs washed free of hematopoietic
cells or in OPG-treated BMSCs. Co-cultures of POBs with BMMs or
with CM fromBMMs demonstrated that RANKL-treated BMMswere re-
quired to see the inhibitory effects of PGs. The need for RANKL in order
to see the inhibitory effects and the reversal by OPG suggest that the
BMMs involved were committed to the OC lineage. Finally, using
these same co-cultures, we showed that PGs acted on BMMs to cause
them to produce a soluble factor or factors that then acted on OBs to
suppress PTH-stimulated OB differentiation.
We could ﬁnd no precedent for a soluble factor produced in OC
lineage cells in response to PGs that inhibited PTH-stimulated OB differ-
entiation. A number of studies have shown that soluble factors produced
bymonocytes and non-resorbing OCs can regulate OB differentiation in a
stimulatory, but not inhibitory, manner [46–51]. Osteal macrophages
(osteomacs), resident macrophages in bone-lining tissues that interact
with OBs, would seem to be ruled out as candidates for producing the
inhibitory factor observed in our study because studies indicate that
they do not become OCs (or at least do not have their regulatory func-
tions if they commit to become OCs) [52–54]. Several studies have
proposed OC-produced factors that, unlike our ﬁndings, are not speciﬁc
for PTH-treated cultures but can inhibit OB differentiation in general.
These factors include cardiotropin-1 [55], semaphorin 4D [56], and
sclerostin [47]. We have done several microarray studies on the BMMs
under our culture conditions and did not ﬁnd differential expression of
any of these factors by COX-2 expression/activity or PGE2 addition
(data not shown), but this does not rule out their regulation at the
protein level.
The inhibition of PTH-stimulated differentiation mediated by
endogenous PGs could be generated by addition of PGE2, but not
other agonists for other PG receptors, to cultures. Moreover, production
of the inhibitory CM required expression on BMMs of EP4, one of two
receptors for PGE2 that activates cAMP signaling. Hence, it seems likely
that the endogenous PG mediating the inhibitory action under our
conditions is PGE2. PGE2 is expected to have its major actions via
cAMP/PKA signaling pathways similar to those stimulated by PTH.
Exogenous PGE2 concentrations as low as 0.1 nMwere sufﬁcient to in-
hibit osteogenic effects of PTH, and levels ≥4 nMwere seen in vehicle-
treated co-cultures of POBs andBMMsas long as one cell type expressed
COX-2. PGE2 itself stimulates OB differentiation in vitro, as shown in the
current studies. For a number of agents, such as TGFβ, BMP2, strontium
ranelate and fresh serum [14,17–19], the induction of COX-2 expression
and PGE2 production enhances their stimulation of OB differentiation
in vitro. In contrast to PTH, these agents all havemajor actions via sig-
naling pathways other than cAMP/PKA. Hence, other agonists that
act via cAMP signaling pathways might also be inhibited by PGE2 in
this culture model.
CM from COX-2 expressing BMMs did not block the stimulatory
effects of endogenous PGs or exogenous PGE2 unless the cultures
were also treated with PTH. In the absence of BMMs, the combination
of PTHwith PGE2 had additive effects on OB differentiation, as expected
of two osteogenic agents. In contrast, in the presence of the as yetunidentiﬁed factor or factors secreted by BMMs, the stimulatory effect
of the combination of PTH and PGE2 was abrogated. Assuming that
the stimulatory effects of PTH and PGE2 on OBs are mediated via stimu-
lation of cAMP, it is possible that the CM contains a factor that acts via
Gαi to inhibit production of PTH- and PGE2-stimulated cAMP. PGE2 in
WT CM can act via EP3, which is coupled to Gαi. However, it is unclear
why this effect would only occur in the presence of PTH. The factor that
blocks PTH-stimulated differentiation produced by BMMs is unlikely to
be PGE2 itself because the addition of PGE2 to PTH, in the absence of
BMMs orWT CM, resulted in additive stimulatory effects. Another pos-
sibility is that PTH induced activity of a phosphodiesterase that rapidly
degraded PGE2-stimulated cAMP, but it is unclear why this should
happen only in the presence ofWT BMMs or CM. Although the explana-
tion awaits further studies, this observation might explain why it has
also been difﬁcult to demonstrate an anabolic effect of systemically
applied PGE2 in mice [57]. Because the inhibitory factor made by
BMMs blocks the stimulatory effects of PGE2 in the presence of PTH
and because endogenous PTH is present continuously in vivo, PGE2
given in vivo might act on BMMs to suppress not only PTH-stimulated
OB differentiation but also its own ability to stimulate OB differentiation.
In our in vitro study, PGE2 is stable in the media (personal observa-
tion), unlike the conditions expected in vivo. PGs in vivo are not stored
but are synthesized, released as needed and rapidly metabolized in
their passage through the lung [58]. COX-2 protein is estimated to
have a half-life on the order of 2 h [59,60], and the local level of PGs
in vivo is highly dependent on new production of Cox-2, which is a rap-
idly inducible and transiently expressed gene [14]. However, even
when PTH was given intermittently, where the interaction of PTH and
PGE2 is expected to be brief, we found that PTH in vivo was more ana-
bolic in Cox-2 KO mice than in WT mice [25]. A more marked effect of
the inhibitory interaction of PTH and PGs on OB differentiation is
expected in the continuous PTH infusion protocol, because both PTH
and PGs should be continuously elevated. In addition, there should
be an abundance of OCs generated by continuous PTH in vivo to pro-
duce the inhibitory factor(s). It is possible, therefore, that the PTH in-
duction of COX-2 could account for some of the bone loss seen with
continuous PTH in vivo.
Our ﬁndings suggest a novel role for COX-2 produced PGE2 in vitro
to inhibit PTH-stimulated osteogenic/anabolic activity via actions
through EP4 on early osteoclastic lineage cells. PGE2 is likely to be
generated by COX-2 induction in many types of culture, and these
ﬁndings suggest that it may have important modulatory roles that are
overlooked. A better understanding of how PGs modulate the actions
of PTH may help us be more effective in targeting bone remodeling for
the treatment of osteoporosis and lead to the future development of
new anabolic agents or protocols to improve therapy for osteoporosis
and other skeletal defects.
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